STATEMENT: BIOGEN PROVIDES UPDATE ON THE ACQUISITION OF REATA PHARMACEUTICALS
Biogen confirms that today Reata Pharmaceuticals announced in a special meeting the stockholders of the company voted to approve the company’s previously announced acquisition by Biogen. For more information, read Reata’s Form 8-K disclosure.
Biogen Announces 2023 Annual Shareholder Meeting Preliminary Results
Cambridge, Mass. – June 26, 2023 – Biogen Inc. (Nasdaq: BIIB) today held its Annual Meeting of shareholders. As previously announced, Caroline Dorsa has succeeded Stelios Papadopoulos as Chair of the Board of Directors at conclusion of the Annual Meeting.
Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program
As part of its ongoing Research & Development (R&D) prioritization initiative and resource allocation, Biogen announced plans to revise the clinical development program for BIIB122, a small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), which is being developed in collaboration with
Biogen Files Form 8-K
Biogen today filed a Form 8-K with the United States Securities and Exchange Commission, disclosing that "On May 3, 2023, the European Commission notified Biogen Inc. of its decision that the period of regulatory market protection for Tecfidera extends until February 2, 2025.”
BIOGEN PUBLISHES 2022 ESG REPORT
Biogen has published its 2022 ESG Report, which supports Biogen’s business goals by sharing our corporate responsibility story, disclosing key environmental, social, and governance (ESG) data and providing updated progress against our targets and commitments. You can find a copy here.
Biogen Announces Publication of BIIB080 Phase 1b Data in Nature Medicine
Nature Medicine has published a manuscript detailing promising results from Biogen’s multiple ascending dose Phase 1b trial, which evaluated the safety, pharmacokinetics and target engagement of Biogen’s BIIB080 (MAPT ASO), an investigational antisense oligonucleotide targeting tau mRNA in
Biogen Shares Update on FDA Advisory Committee Meeting for Tofersen
On January 23, 2023, the Federal Register published a notice that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the Peripheral and Central Nervous System Drugs Advisory Committee for the New Drug Application (NDA) for tofersen, an investigational product for the
A statement from Biogen on LEQEMBI™ pricing
Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBI TM via the Accelerated Approval pathway. Additional details can be found in a news release announcing the approval. An additional news release from Eisai on patient safety
Corporate Statement on Report by the Staffs of the Committee on Oversight and Reform and Committee on Energy and Commerce
Since 2021 Biogen has been working cooperatively with the U.S. House Committee on Oversight and Reform and the U.S. House Energy and Commerce Committee regarding their investigations into the launch of Aduhelm, including providing requested information.
Statement: Biogen Statement On Qui Tam Settlement
Biogen has reached a final agreement to pay $900 million to resolve previously disclosed qui tam litigation relating to speaker and consultant programs conducted by the Company prior to 2015. Biogen believes its intent and conduct was at all times lawful and appropriate and Biogen denies all